Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Sabbagh

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
American Family Physician|June 6, 1998
Pseudoneurologic syndromes: recognition and diagnosisA Shaibani, M N Sabbagh
Panminerva Medica|December 20, 2007
Pathological correlates of cognitive decline in Alzheimer's diseaseK Thind, M N Sabbagh
Journal of Neural Transmission (Vienna, Austria : 1996)|November 22, 2001
Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's diseaseR T Reid, M N Sabbagh, L J Thal
Journal of Alzheimer'S Disease : JAD|September 6, 2002
Amyloid-beta and treatment opportunities for Alzheimer's diseaseM N Sabbagh, D Galasko, E Koo, et al.
Current Neuropharmacology|June 2, 2012
Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's DiseaseL Arab, R Sadeghi, D G Walker, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2021
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021A P Porsteinsson, R S Isaacson, S Knox, et al.
Neurobiology of Aging|October 4, 2000
Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's diseaseR T Rei, M N Sabbagh, J Corey-Bloom, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 1, 2001
Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodiesM N Sabbagh, R T Reid, L A Hansen, et al.
The Journal of Nutrition, Health & Aging|December 11, 2002
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrierD L Sparks, D J Connor, P J Browne, et al.
Archives of Neurology|December 11, 1999
Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer diseaseM N Sabbagh, J Corey-Bloom, P Tiraboschi, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
American Family Physician|June 6, 1998
Pseudoneurologic syndromes: recognition and diagnosisA Shaibani, M N Sabbagh
Panminerva Medica|December 20, 2007
Pathological correlates of cognitive decline in Alzheimer's diseaseK Thind, M N Sabbagh
Journal of Neural Transmission (Vienna, Austria : 1996)|November 22, 2001
Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's diseaseR T Reid, M N Sabbagh, L J Thal
Journal of Alzheimer'S Disease : JAD|September 6, 2002
Amyloid-beta and treatment opportunities for Alzheimer's diseaseM N Sabbagh, D Galasko, E Koo, et al.
Current Neuropharmacology|June 2, 2012
Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's DiseaseL Arab, R Sadeghi, D G Walker, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2021
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021A P Porsteinsson, R S Isaacson, S Knox, et al.
Neurobiology of Aging|October 4, 2000
Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's diseaseR T Rei, M N Sabbagh, J Corey-Bloom, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|December 1, 2001
Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodiesM N Sabbagh, R T Reid, L A Hansen, et al.
The Journal of Nutrition, Health & Aging|December 11, 2002
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrierD L Sparks, D J Connor, P J Browne, et al.
Archives of Neurology|December 11, 1999
Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer diseaseM N Sabbagh, J Corey-Bloom, P Tiraboschi, et al.
Pageof 4